Market Overview

Idera Pharma Shares Could Be A Four-Bagger, JMP Says

Share:

Idera Pharmaceuticals Inc (NASDAQ: IDRA) is a clinical-stage biopharmaceutical company developing novel nucleic acid-based product candidates for the treatment of cancer and rare diseases. The company is “capable of generating a host of promising drug candidates,” JMP Securities’ Michael King said in a report.

King initiated coverage of the company with a Market Outperform rating and price target of $8.

Idera Pharma was founded on the basis of pioneering work in the field of antisense oligonucleotides and has a “best-of-breed nucleic acid therapeutic platform” that could generate a large number of promising drug candidates, the analyst mentioned.

The company has entered into the immuno-oncology [IO] space, which is a strategic move. Its lead IO asset, IMO-2125, has exhibited “impressive clinical activity in combination with checkpoint inhibition in the setting of anti-PD-1 refractory metastatic melanoma,” King noted.

Related Link: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update

Key Positives

The analyst mentioned the following positives that combine to make Idera Pharma “an attractive investment opportunity in the small-cap biotech space”

  1. Innovative platform
  2. Strong scientific foundation
  3. Seasoned management team
  4. Assets with demonstrated clinical activity

Latest Ratings for IDRA

DateFirmActionFromTo
Sep 2019JMP SecuritiesAssumesMarket Outperform
Sep 2018BarclaysInitiates Coverage OnOverweight
Jul 2018WedbushMaintainsOutperformOutperform

View More Analyst Ratings for IDRA
View the Latest Analyst Ratings

 

Related Articles (IDRA)

View Comments and Join the Discussion!

Posted-In: JMP Securities Michael KingAnalyst Color Long Ideas Price Target Initiation Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
BIIBRBC CapitalMaintains277.0
RLICompass PointInitiates Coverage On90.0
CSCOWolfe ResearchDowngrades42.0
NKEBarclaysMaintains132.0
GILDRBC CapitalMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com